Department of General Anesthesiology, Anesthesiology Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA; Department of Anesthesiology, Division of Critical Care Medicine, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8054, St Louis, MO 63110, USA.
Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Emory University School of Medicine, Emory St. Joseph's Hospital, 5665 Peachtree Dunwoody Road, Atlanta, GA 30342, USA.
Crit Care Clin. 2019 Apr;35(2):229-245. doi: 10.1016/j.ccc.2018.11.003. Epub 2019 Jan 23.
The Angiotensin II for the Treatment of Vasodilatory Shock (ATHOS-3) trial demonstrated the vasopressor effects and catecholamine-sparing properties of angiotensin II. As a result, the Food and Drug Administration has approved angiotensin II for the treatment of vasodilatory shock. This review details the goals of treatment of vasodilatory shock in addition to the history, current use, and recent research regarding the use of angiotensin II. An illustrative case of the use of angiotensin II is also incorporated for understanding the clinical utility of the drug.
血管扩张性休克的血管紧张素 II 治疗（ATHOS-3）试验证明了血管紧张素 II 的升压作用和儿茶酚胺节约特性。因此，食品和药物管理局已批准血管紧张素 II 用于治疗血管扩张性休克。本综述详细介绍了血管扩张性休克的治疗目标，以及血管紧张素 II 的历史、当前用途和最近的研究。还纳入了一个使用血管紧张素 II 的病例来说明药物的临床应用。
